TABLE 2.
Survival rates after EBRT and results of univariate and multivariate analyses
| 0.5‐year (%) | 1‐year (%) | Univariate analysis | Multivariate analysis | Regression coefficient | ||||
|---|---|---|---|---|---|---|---|---|
| HR (95% CI) | p | HR (95% CI) | p | |||||
| Age | <70 years vs. ≥70 years | 51.3 vs. 37.5 | 34.0 vs. 24.3 | 1.23 (0.98–1.55) | 0.07 | – | – | – |
| Sex | Female vs. male | 49.7 vs. 42.1 | 38.5 vs. 24.6 | 1.25 (0.98–1.59) | 0.07 | – | – | – |
| ECOG‐PS | 0–2 vs. 3–4 | 52.6 vs. 32.9 | 35.7 vs. 20.8 | 1.50 (1.19–1.89) | <0.01 | 1.59 (1.22–2.07) | <0.01 | 0.24 |
| Histology | NSCLC vs. SCLC | 45.4 vs. 38.4 | 30.4 vs. 20.7 | 1.21 (0.84–1.75) | 0.30 | – | – | – |
| Smoking history | No vs. yes | 58.7 vs. 43.1 | 46.2 vs. 25.9 | 1.49 (1.12–1.98) | 0.01 | 1.03 (0.76–1.39) | 0.86 | 0.02 |
| Timing of RT | De novo vs. relapse or appearance | 47.5 vs. 43.2 | 34.2 vs. 27.0 | 1.12 (0.88–1.42) | 0.37 | – | – | – |
| Metastases on internal organs | No vs. yes | 65.6 vs. 39.3 | 48.7 vs. 24.4 | 1.87 (1.39–2.52) | <0.01 | 1.86 (1.33–2.60) | <0.01 | 0.31 |
| Number of bone metastatic lesions | 1 vs. ≥2 | 63.7 vs. 38.4 | 40.5 vs. 25.7 | 1.55 (1.19–2.03) | <0.01 | 1.28 (0.97–1.69) | 0.08 | 0.13 |
| Bone metastatic sites | Only spine vs. others | 51.6 vs. 42.6 | 36.3 vs. 27.7 | 1.21 (0.92–1.59) | 0.16 | – | – | – |
| Neurological symptom | No vs. yes | 47.1 vs. 35.1 | 31.4 vs. 23.4 | 1.13 (0.85–1.50) | 0.40 | – | – | – |
| Pathological fracture | No vs. yes | 45.5 vs. 40.6 | 30.3 vs. 25.4 | 1.05 (0.78–1.43) | 0.74 | – | – | – |
| Pre‐RT ATs | MTs vs. others | 49.0 vs. 43.4 | 28.7 vs. 29.7 | 1.00 (0.77–1.31) | 0.99 | – | – | – |
| Post‐RT ATs | MTs vs. others | 85.3 vs. 24.7 | 68.2 vs. 10.0 | 4.38 (3.32–5.79) | <0.01 | 4.74 (3.42–6.56) | <0.01 | 0.79 |
| Pre‐RT laboratory data | Normal vs. abnormal | 80.8 vs. 41.8 | 57.7 vs. 27.2 | 2.01 (1.27–3.17) | <0.01 | 1.45 (0.83–2.53) | 0.19 | 0.17 |
Abbreviations: ATs, antineoplastic agents; ECOG PS, Eastern Cooperative Oncology Group Performance Status; MTs, molecular‐targeting therapy (tyrosine kinase inhibitors or immune checkpoint inhibitors); NSCLC, non‐small cell lung cancer; RT, radiotherapy; SCLC, small cell lung cancer.